PHILADELPHIA, PA — Proscia® has introduced Proscia Aperture™, an AI-driven precision medicine solution designed to transform routine pathology data into real-time patient insights, enabling faster development of targeted therapies and expanding patient access to next-generation treatments.
Aperture connects a global laboratory network projected to deliver 8 million pathology diagnoses annually through Proscia’s Concentriq® platform, leveraging AI to analyze tissue images, molecular results, clinical records, and AI-derived biomarkers. These insights support regulatory submissions, companion diagnostic development, label expansions, and payer negotiations, while simultaneously surfacing eligible clinical trial candidates at the point of diagnosis.
The launch addresses a critical gap in precision medicine. Fewer than one in ten cancer patients enroll in clinical trials, leaving many without access to breakthrough therapies. With digital pathology advancing, Aperture places laboratories at the center of innovation by unlocking rich disease profiles from tissue images that historically remained disconnected from drug development.
“Aperture demonstrates that pathology is no longer the end of the diagnostic journey but the driver of what comes next for patients,” said David West, CEO of Proscia. “By unlocking insights at the moment of diagnosis, we unite research and care, making the future of pathology a reality.”
Aperture also leverages Proscia’s repository of over 12 million tissue images paired with clinical and genomic records, broadening the scale and diversity of available real-world data while maintaining strict patient privacy through de-identification and governance protocols.
For diagnostic laboratories, Aperture introduces new revenue opportunities and enhances their role in advancing drug development. By integrating into clinical workflows, it helps laboratories differentiate their services, strengthen partnerships with biopharmaceutical companies, and position themselves as essential contributors to research and innovation amid shrinking margins and workforce challenges.
Industry leaders see Aperture as a significant step forward. Nina Green, Vice President and General Manager of the Clinical Diagnostics Division at Agilent Technologies, noted that the platform “opens an avenue with the potential to advance clinical trials, companion diagnostic development, and broaden patient access.”
With its AI-powered capabilities, Proscia Aperture is poised to bridge the gap between diagnosis and treatment, supporting scientists, healthcare providers, and biopharmaceutical companies while expanding opportunities for patients to benefit from emerging precision therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.